Eli Lilly Joins Chase for Hot Inflammation Target, Paying $100M for Rights to CSL Drug Read More February 18, 2026
Addressing the 58% Launch Failure Rate: Accelerating Market Access Through Intelligent Decision-Making Read More February 18, 2026
Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test Read More February 17, 2026
Regulatory Innovation as a Catalyst: How New Compliance Strategies Are Speeding Up Healthcare Technology Adoption Read More February 17, 2026
The Future of Pharmacy is Now – Health Systems Must Act to Drive Innovation, Access and Sustainability Read More February 17, 2026
Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA Read More February 16, 2026
From Pilots to Protocols: Why VR Therapy Needs Dosage Standards to Become Real Clinical Care Read More February 16, 2026
